Ara-290 10mg by Ozpharm

ARA-290 10 mg – Ozpharm | Cibinetide Research Peptide

Introduction

ARA-290 10 mg, manufactured by Ozpharm, refers to ARA-290 (Cibinetide), an 11-amino-acid peptide derived from the helix-B region of erythropoietin (EPO). Unlike erythropoietin, ARA-290 is designed to activate the innate repair receptor (IRR) without stimulating erythropoiesis.

ARA-290 has been investigated for its potential role in tissue protection, inflammatory signaling, nerve repair, and neuropathic symptoms. Research has particularly examined its effects in conditions involving small-fiber nerve damage and inflammation.

Product Details

• Product Name: ARA-290 10 mg

• Manufacturer: Ozpharm

• Active Peptide: ARA-290 / Cibinetide

• Peptide Length: 11 amino acids

• Origin: Derived from the helix-B region of erythropoietin

• Mechanism Under Research: Innate repair receptor activation

• Research Category: Tissue protection / neuroprotection / inflammatory research

• Typical Research Format: Peptide preparation, depending on manufacturer

• Intended Use: Scientific and laboratory research

• Human Therapeutic Status: Investigational

Benefits and Research Properties of ARA-290

ARA-290 has attracted research interest because of its potential tissue-protective and anti-inflammatory properties. These findings should be considered research outcomes rather than established therapeutic benefits.

Key Research Areas

• Research into tissue-protective mechanisms

• Investigation of inflammatory signaling

• Study of peripheral nerve repair

• Research into small-fiber neuropathy

• Investigation of neuropathic pain pathways

• Study of neuroprotective mechanisms

• Research into immune-system signaling

• Investigation of cellular repair pathways

• Research into oxidative stress and inflammation

• Study of the innate repair receptor

Clinical research in sarcoidosis-associated small-fiber neuropathy found improvements in neuropathic symptoms and increases in corneal small-nerve-fiber density following experimental ARA-290 treatment.

Common Research Combinations

ARA-290 is primarily studied in controlled experimental settings rather than as part of standardized bodybuilding or wellness combinations.

ARA-290 + Neuropathy Research

ARA-290 has been investigated in clinical research involving small-fiber neuropathy associated with sarcoidosis, including assessments of neuropathic symptoms and nerve-fiber density.

ARA-290 + Inflammation Research

Research has examined ARA-290 in relation to inflammatory pathways and tissue-protective mechanisms.

ARA-290 + Nerve Repair Research

The peptide is being studied for its potential involvement in mechanisms associated with peripheral nerve protection and repair.

ARA-290 + Tissue Protection Research

Preclinical studies have investigated ARA-290 in models of tissue injury, oxidative stress, inflammation, and cellular damage.

Cycle and Research Protocol

There is no universally approved human ARA-290 10 mg cycle for routine self-administration.

Clinical research has used different experimental doses and treatment durations depending on the condition being investigated. For example, a Phase 2 sarcoidosis study evaluated 1 mg, 4 mg, and 8 mg daily subcutaneous ARA-290 for 28 days. These study protocols are research designs and should not be interpreted as recommendations for personal use.

Another Phase 2 study investigating diabetic macular edema evaluated 4 mg/day subcutaneous cibinetide for 12 weeks. The small study reported no serious adverse events, but its findings were exploratory and require further investigation.

Therefore, the 10 mg product strength should not be confused with an approved 10 mg human treatment regimen. Any research protocol should be determined according to the specific experimental model, scientific objective, and applicable laboratory or clinical-study requirements.

Possible Side Effects and Safety Considerations

Because ARA-290 remains investigational, its complete long-term safety profile has not been established.

Reported Research Findings

Clinical studies have generally reported encouraging tolerability, although the available studies were relatively limited in size and duration.

A Phase 2 diabetic macular edema study involving 9 participants reported no serious adverse events or anti-cibinetide antibodies during the 12-week study period.

Potential Safety Considerations

Research involving ARA-290 requires attention to:

• Injection-site reactions

• Possible hypersensitivity reactions

• Changes in inflammatory or immune signaling

• Unknown long-term effects

• Product purity and sterility

• Potential effects that have not yet been identified in larger studies

The absence of serious adverse events in a small clinical study does not establish long-term safety for general use.

Limited Long-Term Safety Data

Because ARA-290 has not established the same regulatory and clinical history as approved medicines, long-term safety data remain limited. Additional large-scale studies are necessary to fully characterize its safety profile.

Who Uses ARA-290 10 mg?

ARA-290 research material may be relevant to:

• Pharmaceutical research laboratories

• Peptide research programs

• Neuroscience research

• Neuropathy research

• Inflammation research

• Tissue-repair studies

• Neuroprotection research

• Immunology research

• Pharmacology research

• Academic and biomedical research

ARA-290 should be handled according to the applicable laboratory safety procedures and manufacturer documentation.

Storage Instructions

Storage conditions depend on the specific formulation and manufacturer specifications.

For research-grade ARA-290:

• Follow the storage conditions supplied with the product.

• Protect the material from excessive heat and moisture.

• Protect from direct light when specified.

• Maintain the product according to the manufacturer's documentation.

• Do not use material if the packaging or product integrity appears compromised.

• Follow appropriate laboratory handling and safety procedures.

Research Disclaimer

ARA-290 10 mg is an investigational research peptide and should not be represented as an approved treatment for neuropathy, inflammation, tissue damage, diabetes, or any other medical condition without appropriate regulatory authorization.

Research findings do not automatically establish clinical efficacy or safety. Any therapeutic application requires appropriate clinical evidence, regulatory approval, and qualified medical supervision.

Conclusion

ARA-290 10 mg by Ozpharm refers to a preparation containing ARA-290 (Cibinetide), an 11-amino-acid peptide derived from erythropoietin's helix-B region. ARA-290 is designed to interact with the innate repair receptor and has been investigated for tissue-protective, anti-inflammatory, neuroprotective, and nerve-repair mechanisms.

Clinical research has explored ARA-290 in conditions including sarcoidosis-associated small-fiber neuropathy and diabetic macular edema, with some studies reporting encouraging findings involving neuropathic symptoms and nerve-fiber measures. However, these findings remain investigational and require further clinical research.